Siemens Launches New High-Volume Coagulation Analyzer Enabling Labs to Achieve First-Run Accuracy
Preanalytical Sample Integrity technology enhances efficiency with automated preanalytical sample management
Tarrytown, N.Y., January 2, 2013 – Siemens Healthcare Diagnostics launches the Sysmex® CS-5100 System, a random access high-volume coagulation analyzer, in multiple markets across the world, including Europe, Africa, Canada, Latin America, Australia and New Zealand.1 This latest addition to the Siemens Sysmex CS portfolio is equipped with simultaneous, multi-wavelength Preanalytical Sample Integrity (PSI) technology, enabling high-volume laboratories to achieve first-run accuracy by identifying and managing unsuitable test specimens prior to analysis.
Preanalytical errors and unsuitable samples account for up to 70 percent of mistakes in the lab.2 For example, under-filling sample tubes may cause significant sample dilution and provide falsely prolonged clotting times.3 Also, hemolytic specimens are the leading cause of preanalytical variability and have been shown to negatively affect medical care.4 Leveraging PSI technology, the Sysmex CS-5100 system automates and standardizes sample management, detecting unsuitable samples prior to analysis. This technology enhances results reliability while improving efficiency by minimizing the need for manual sample inspections.
“With steadily increasing patient test volumes coupled with growing demand to produce results quickly, hemostasis laboratories require a solution that allows them to effectively balance higher throughput without compromising accuracy,” said Stefan Wolf, CEO, Hemostasis, Hematology and Specialty Business Unit, Siemens Healthcare Diagnostics. “We are pleased to provide our customers with a high-volume system that helps them address these challenges.”
The Sysmex CS-5100 system also features third-generation cap-piercing technology, which contributes to reduced sample processing time and maintains the analyzer’s high throughput capability. Greater efficiency is also gained via a wide optical spectrum, which allows clotting, chromogenic, immunologic and agglutination testing capabilities on a single platform. Additionally, with onboard capacity of up to 3,000 tests5 and up to 40 reagents, the Sysmex CS-5100 system delivers extended walkway time to streamline workflow.
Further, in an effort to ensure results consistency and simplify the hemostasis testing process in multi-site labs, Sysmex CS-5100 system test results correlate with all other Siemens Sysmex CS and CA hemostasis systems. Plus, the CS-5100 system also uses the same reagents, controls, calibrators and consumables.6
The company plans to connect the Sysmex CS-5100 system to its automation and data-management solutions to help labs further consolidate workflow.7 For more information about the Sysmex CS 5100 system, please visit: http://healthcare.siemens.com/hemostasis/systems/sysmex-cs-5100-system. The introduction of this new coagulation analyzer is a demonstration of Siemens’ efforts to grow its innovative capacity, which is a goal of Siemens Agenda 2013 program.
1 Disclaimer: The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details. Not available for sale in the United States.
2 Lippi G, Banfi G, Buttarello M, et al. Recommendations for detection and management of unsuitable samples in clinical laboratories. Clin Chem Lab Med. 2007;45(6):728-736.
3 Favaloro E, Lippi G, Adcock D. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost. 2008;34:612-634.
4 Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med. 2008;46(6):764-772.
5 Based on internal validation data from Sysmex Corporation.
6 Excludes Sysmex CA Systems consumables.
7 The product is still under development and not commercially available yet. Its future availability cannot be ensured.
Launched by Siemens Healthcare Sector in November 2011, Agenda 2013 program is a two-year global initiative to further strengthen the Healthcare Sector’s innovative power and competitiveness. Specific measures will be implemented in four fields of action: Innovation, Competitiveness, Regional Footprint, and People Development.
The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2012 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of 1.8 billion euros. For further information please visit: www.siemens.com/healthcare.
Contact: Sue Drew
email: [email protected]
Follow us on Twitter: www.twitter.com/SiemensHealth